Unknown

Dataset Information

Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib.


ABSTRACT:

Background

The 'Prediction Of Survival in Advanced Sorafenib-treated HCC' (PROSASH) model addressed the heterogeneous survival of patients with hepatocellular carcinoma (HCC) treated with sorafenib in clinical trials but requires validation in daily clinical practice. This study aimed to validate, compare and optimize this model for survival prediction.

Methods

Patients treated with sorafenib for HCC at five tertiary European centres were retrospectively staged according to the PROSASH model. In addition, the optimized PROSASH-II model was developed using the data of four centres (training set) and tested in an independent dataset. These models for overall survival (OS) were then compared with existing prognostic models.

Results

The PROSASH model was validated in 445

SUBMITTER: Labeur TA 

PROVIDER: S-EPMC6973249 | biostudies-literature | 2020 Jan

REPOSITORIES: biostudies-literature